Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.

Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, Jeeninga R, Smits S, Trevejo J, Shriver Z, Oldach D.

EBioMedicine. 2019 Feb;40:574-582. doi: 10.1016/j.ebiom.2018.12.051. Epub 2019 Jan 9.

2.

Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study.

Yu B, Adedoyin A, Hershberger E, Caro L, Xiao A, Rhee EG, Huntington JA.

Clin Pharmacol Drug Dev. 2018 May;7(4):382-391. doi: 10.1002/cpdd.429. Epub 2018 Mar 8.

PMID:
29517862
3.

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.

Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS.

J Antimicrob Chemother. 2017 Jan;72(1):268-272. Epub 2016 Oct 5.

PMID:
27707990
4.

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.

Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4387-90. doi: 10.1128/AAC.03074-15. Print 2016 Jul.

5.

Response to Spellberg and Brass.

Solomkin JS, Hershberger E, Eckmann C.

Clin Infect Dis. 2016 Feb 15;62(4):526. doi: 10.1093/cid/civ896. Epub 2015 Oct 20. No abstract available.

PMID:
26486708
6.

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.

Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10.

7.

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.

Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G.

J Clin Pharmacol. 2015 Feb;55(2):230-9. doi: 10.1002/jcph.395. Epub 2014 Nov 14.

8.

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin J.

Antimicrob Agents Chemother. 2014 Sep;58(9):5350-7. doi: 10.1128/AAC.00049-14. Epub 2014 Jun 30.

9.

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G.

Antimicrob Agents Chemother. 2014;58(4):2249-55. doi: 10.1128/AAC.02151-13. Epub 2014 Feb 3.

10.

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Miller B, Hershberger E, Benziger D, Trinh M, Friedland I.

Antimicrob Agents Chemother. 2012 Jun;56(6):3086-91. doi: 10.1128/AAC.06349-11. Epub 2012 Mar 26.

11.

Safety and clinical outcomes among older adults receiving daptomycin therapy: Insights from a patient registry.

DePestel DD, Hershberger E, Lamp KC, Malani PN.

Am J Geriatr Pharmacother. 2010 Dec;8(6):551-61. doi: 10.1016/S1543-5946(10)80004-2.

PMID:
21356504
12.

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.

Ann Pharmacother. 2009 Jul;43(7):1211-9. doi: 10.1345/aph.1M085. Epub 2009 Jul 7.

PMID:
19584384
13.

Quinupristin-dalfopristin resistance in Enterococcus faecium isolates from humans, farm animals, and grocery store meat in the United States.

Donabedian SM, Perri MB, Vager D, Hershberger E, Malani P, Simjee S, Chow J, Vergis EN, Muder RR, Gay K, Angulo FJ, Bartlett P, Zervos MJ.

J Clin Microbiol. 2006 Sep;44(9):3361-5.

14.

Epidemiology of antimicrobial resistance in enterococci of animal origin.

Hershberger E, Oprea SF, Donabedian SM, Perri M, Bozigar P, Bartlett P, Zervos MJ.

J Antimicrob Chemother. 2005 Jan;55(1):127-30. Epub 2004 Dec 1.

PMID:
15574473
15.

Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis.

Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ.

J Antimicrob Chemother. 2004 Apr;53(4):626-30. Epub 2004 Feb 18.

PMID:
14973150
16.

Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, Kuyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ.

Clin Infect Dis. 2003 Dec 15;37(12):1643-8. Epub 2003 Nov 20.

PMID:
14689346
17.

Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.

Hershberger E, Donabedian S, Konstantinou K, Zervos MJ.

Clin Infect Dis. 2004 Jan 1;38(1):92-8. Epub 2003 Dec 5.

PMID:
14679454
18.

Antimicrobial resistance in swine and chickens fed virginiamycin for growth promotion.

Donabedian S, Thal LA, Bozigar P, Zervos T, Hershberger E, Zervos M.

J Microbiol Methods. 2003 Dec;55(3):739-43.

PMID:
14607416
19.

Antimicrobial resistance among gram-positive organisms in the intensive care unit.

Clark NM, Hershberger E, Zervosc MJ, Lynch JP 3rd.

Curr Opin Crit Care. 2003 Oct;9(5):403-12. Review.

PMID:
14508154
20.

Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food.

Donabedian SM, Thal LA, Hershberger E, Perri MB, Chow JW, Bartlett P, Jones R, Joyce K, Rossiter S, Gay K, Johnson J, Mackinson C, Debess E, Madden J, Angulo F, Zervos MJ.

J Clin Microbiol. 2003 Mar;41(3):1109-13.

21.

The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Alam MR, Hershberger E, Zervos MJ.

Curr Infect Dis Rep. 2002 Oct;4(5):426-432.

PMID:
12228030
22.

In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin.

Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ.

Diagn Microbiol Infect Dis. 2002 Apr;42(4):269-71.

PMID:
12007445
23.

Molecular analysis of vancomycin-resistant Enterococcus faecalis from Michigan hospitals during a 10 year period.

Malani PN, Thal L, Donabedian SM, Robinson-Dunn B, Kauffman CA, Chow JW, Hershberger E, Zervos MJ.

J Antimicrob Chemother. 2002 May;49(5):841-3.

PMID:
12003981
24.

Thrombocytopenia associated with linezolid therapy.

Attassi K, Hershberger E, Alam R, Zervos MJ.

Clin Infect Dis. 2002 Mar 1;34(5):695-8. Epub 2002 Jan 17.

PMID:
11803505
25.

Heteroresistance to vancomycin in Enterococcus faecium.

Alam MR, Donabedian S, Brown W, Gordon J, Chow JW, Zervos MJ, Hershberger E.

J Clin Microbiol. 2001 Sep;39(9):3379-81.

27.

PCR fragment length polymorphism analysis of vancomycin-resistant Enterococcus faecium.

Donabedian S, Hershberger E, Thal LA, Chow JW, Clewell DB, Robinson-Dunn B, Zervos MJ.

J Clin Microbiol. 2000 Aug;38(8):2885-8.

28.

Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.

Hershberger E, Coyle EA, Kaatz GW, Zervos MJ, Rybak MJ.

Antimicrob Agents Chemother. 2000 Jul;44(7):1921-4.

29.

Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function.

Neuhauser MM, McKinnon PS, Hershberger E, Rybak MJ.

Pharmacotherapy. 2000 May;20(5):554-61.

PMID:
10809342
33.
35.

Cultural implications for nursing care of the Amish.

Beachy A, Hershberger E, Davidhizar R, Giger JN.

J Cult Divers. 1997 Winter;4(4):118-26; quiz 127-8. Review.

PMID:
9555377
36.

Morphine blocks the increase in acid phosphatase in the substantia gelatinosa during pain.

Hershberger EA, Kantner RM, Kirby ML.

Neurosci Lett. 1983 Mar 14;35(3):307-10.

PMID:
6843906

Supplemental Content

Loading ...
Support Center